<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1472342</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2024.1472342</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Sustainable synthesis of antibacterial 3-aryl-2<italic>H</italic>-benzo[b,1,4]oxazin-2-ones via S<sub>N</sub>Ar Csp<sup>2</sup>&#x2013;Csp<sup>2</sup> coupling</article-title>
<alt-title alt-title-type="left-running-head">Salehzadeh et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2024.1472342">10.3389/fchem.2024.1472342</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Salehzadeh</surname>
<given-names>Fatemeh</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Esmkhani</surname>
<given-names>Maryam</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2849924/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noori</surname>
<given-names>Milad</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Javanshir</surname>
<given-names>Shahrzad</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1059006/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Iraji</surname>
<given-names>Aida</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/841664/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mahdavi</surname>
<given-names>Mohammad</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Pharmaceutical and Heterocyclic Compounds Research Laboratory</institution>, <institution>Department of Chemistry</institution>, <institution>Iran University of Science and Technology</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Stem Cells Technology Research Center</institution>, <institution>Shiraz University of Medical Sciences</institution>, <addr-line>Shiraz</addr-line>, <country>Iran</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Persian Medicine</institution>, <institution>Research Center for Traditional Medicine and History of Medicine</institution>, <institution>School of Medicine</institution>, <institution>Shiraz University of Medical Sciences</institution>, <addr-line>Shiraz</addr-line>, <country>Iran</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Endocrinology and Metabolism Research Center</institution>, <institution>Endocrinology and Metabolism Clinical Sciences Institute</institution>, <institution>Tehran University of Medical Sciences</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/974735/overview">Siva S. Panda</ext-link>, Augusta University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2277170/overview">Sagnik Sengupta</ext-link>, University of Texas Southwestern Medical Center, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1173559/overview">Tahir Farooq</ext-link>, Government College University Faisalabad, Pakistan</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Shahrzad Javanshir, <email>shjavan@iust.ac.ir</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>11</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>1472342</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>07</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Salehzadeh, Esmkhani, Noori, Javanshir, Iraji and Mahdavi.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Salehzadeh, Esmkhani, Noori, Javanshir, Iraji and Mahdavi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The increasing prevalence of antibiotic-resistant pathogens necessitates the urgent development of new antibacterial agents. Concurrently, synthetic chemistry is moving towards more sustainable practices that minimize environmental impact. This study aims to synthesize 3-aryl-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one derivatives, including the natural product cephalandole A, using a sustainable approach that avoids metal catalysts.</p>
</sec>
<sec>
<title>Methods</title>
<p>We employed nucleophilic aromatic substitution (SNAr) under microwave-assisted conditions to facilitate the synthesis of the targeted compounds. This metal-free carbon&#x2013;carbon coupling reaction was optimized for efficiency, yielding good results with reduced reaction times. The synthesized derivatives were then subjected to an <italic>in silico</italic> molecular docking study to predict their antibacterial potential against key bacterial targets, focusing on the binding affinity and interaction profiles.</p>
</sec>
<sec>
<title>Results</title>
<p>The microwave-assisted SNAr method provided good yields of 55% to 82% and significantly reduced reaction times ranging from 7 to 12 minutes, simplifying the overall workup process. Among the synthesized compounds, 3-(<italic>1H</italic>-indol-3-yl)-6-methyl-2H-benzo[b][1,4]oxazin-2-one (<bold>6b</bold>) emerged as a promising candidate, demonstrating favorable binding interactions in the molecular docking studies.</p>
</sec>
<sec>
<title>Discussion</title>
<p>The integration of sustainable synthetic methodologies with in silico screening offers a novel and effective strategy for drug discovery. Our findings highlight the potential of the synthesized compounds as antibacterial agents and emphasize the importance of adopting eco-friendly approaches in pharmaceutical chemistry. This research contributes to the global effort to combat antibiotic resistance by providing new compounds for further biological evaluation.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Csp 2&#x2013;Csp 2 cross-coupling reactions</kwd>
<kwd>microwave-assisted organic synthesis</kwd>
<kwd>nucleophilic aromatic substitution</kwd>
<kwd>antimicrobial</kwd>
<kwd>natural product cephalandole A</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Organic Chemistry</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Bacterial antibiotic resistance is a critical global health concern that poses a significant threat to human society. This phenomenon occurs when bacteria develop mechanisms to withstand the effects of antibiotics, rendering these medications less or entirely ineffective (<xref ref-type="bibr" rid="B35">Uddin et al., 2021</xref>). Two noteworthy bacterial species, <italic>Mycobacterium tuberculosis</italic> and <italic>Streptococcus dysgalactiae</italic>, have garnered particular attention due to their growing antibiotic resistance. <italic>Mycobacterium tuberculosis</italic> is the causative agent of tuberculosis, a devastating infectious disease that primarily affects the lungs but can also affect other organs. Tuberculosis has been a major global health problem for centuries, and the emergence of antibiotic resistance in <italic>M. tuberculosis</italic> strains has compounded the challenges associated with its control and treatment (<xref ref-type="bibr" rid="B2">Batt et al., 2020</xref>). Similarly, <italic>S. dysgalactiae</italic> is a bacterial species that can cause a range of infections in humans, including skin and soft tissue infections, invasive bloodstream infections, and streptococcal toxic shock syndrome. These strains resist the most potent and commonly used antibiotics, such as isoniazid and rifampicin, making treatment considerably more complex, costly, and less effective (<xref ref-type="bibr" rid="B9">Commons et al., 2014</xref>; <xref ref-type="bibr" rid="B8">Ciszewski et al., 2016</xref>; <xref ref-type="bibr" rid="B24">Nevanlinna et al., 2023</xref>). Antibiotic resistance in <italic>S. dysgalactiae</italic> is particularly concerning for antibiotics like beta-lactams (e.g., penicillin) and macrolides. Resistance mechanisms in these bacteria may involve the production of beta-lactamases, enzymes that break down beta-lactam antibiotics, rendering them ineffective (<xref ref-type="bibr" rid="B34">Tang et al., 2023</xref>; <xref ref-type="bibr" rid="B21">Mathavan et al., 2024</xref>).</p>
<p>Given the escalating threat of antibiotic resistance, the development of new antimicrobial agents is essential to combat resistant strains, prevent the spread of untreatable infections, and in global health protection (<xref ref-type="bibr" rid="B22">Miethke et al., 2021</xref>). Benzoxazines, as versatile heterocyclic compounds, have emerged as foundational components in synthesizing pharmaceutical compounds. The ability to modify the benzoxazine structure allows for the design of new compounds with tailored properties for specific therapeutic applications, making them invaluable in the development of new synthetic drugs. The ability to modify the benzoxazine structure allows for the design of new compounds with tailored properties for specific therapeutic applications. This versatility is crucial in the development of new synthetic drugs. Benzoxazine derivatives have been evaluated for their potential as drug leads. Modification of the benzoxazine scaffold can lead to improved potency and selectivity for specific biological targets (<xref ref-type="bibr" rid="B34">Tang et al., 2023</xref>; <xref ref-type="bibr" rid="B21">Mathavan et al., 2024</xref>). Different derivatives were developed as antimicrobial agents, including quinoline, thiazole<sup>7</sup>, chalcone<sup>8</sup>, naphthoquinone<sup>9</sup>, and fluorouracil (<xref ref-type="bibr" rid="B27">Patil et al., 2023</xref>). Benzoxazines, as versatile heterocyclic compounds, play a pivotal role as foundational components in synthesizing pharmaceutical compounds. They are prevalent in natural products and biologically active molecules, exemplified by their presence as antibacterial (<xref ref-type="bibr" rid="B23">Mitscher et al., 1987</xref>), anticancer (<xref ref-type="bibr" rid="B19">L&#xf3;pez-Iglesias et al., 2015</xref>), antifungal (<xref ref-type="bibr" rid="B37">Waisser et al., 2002</xref>), antibiotic (<xref ref-type="bibr" rid="B17">Kushwaha et al., 2020</xref>), antinociceptive agents (<xref ref-type="bibr" rid="B42">Zumbra&#x308;gel et al., 2018</xref>), and others. <xref ref-type="fig" rid="F1">Figure 1</xref> illustrates a selection of representative benzoxazine pharmacophores (compounds <bold>A&#x2013;C</bold>) known for their antimicrobial properties.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Illustrates a selection of representative benzoxazine pharmacophores (compounds A&#x2013;F) known for their antimicrobial properties. (<xref ref-type="bibr" rid="B13">Hoemann et al., 2000</xref>; <xref ref-type="bibr" rid="B33">Singh and Thakur, 2014</xref>; <xref ref-type="bibr" rid="B38">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="B28">Qin et al., 2020</xref>; <xref ref-type="bibr" rid="B25">Nieto and Lupton, 2021</xref>; <xref ref-type="bibr" rid="B41">Zhao et al., 2023</xref>).</p>
</caption>
<graphic xlink:href="fchem-12-1472342-g001.tif"/>
</fig>
<p>In recent years, there has been a growing body of research works on biologically active compounds with potential as antibacterial agents. Notably, indole-based derivatives (compounds <bold>D&#x2013;F</bold>) have garnered significant attention for their remarkable efficacy as antimicrobial agents, as evidenced by numerous studies (<xref ref-type="bibr" rid="B13">Hoemann et al., 2000</xref>; <xref ref-type="bibr" rid="B4">Burchak et al., 2011</xref>; <xref ref-type="bibr" rid="B38">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="B28">Qin et al., 2020</xref>; <xref ref-type="bibr" rid="B25">Nieto and Lupton, 2021</xref>).</p>
<p>The importance of drug discovery cannot be overstated, particularly in the context of developing new therapies to address global health challenges like antibiotic resistance. Traditional drug development processes can take several years, consuming significant time, money, and resources. In contrast, <italic>in silico</italic> drug design has emerged as a revolutionary approach capable of reducing the timeline of drug discovery from years to just days or months. This method not only conserves financial resources and energy but also significantly enhances the efficiency and accuracy of drug development (<xref ref-type="bibr" rid="B3">Boyd et al., 2021</xref>; <xref ref-type="bibr" rid="B30">Roney and Mohd Aluwi, 2024</xref>).</p>
<p>
<italic>In silico</italic> drug design offers a powerful toolset to predict and optimize the pharmacological profiles of potential drug candidates. It enables the rapid screening of large libraries of compounds, identifying those with the most promising biological activity. This approach has been particularly impactful in the field of antimicrobial drug discovery, where it has facilitated the emergence of novel drug candidates designed to target resistant microbial strains (<xref ref-type="bibr" rid="B15">Jabalia et al., 2021</xref>; <xref ref-type="bibr" rid="B6">Chang et al., 2022</xref>). The ability to predict molecular interactions, binding affinities, and potential off-target effects allows <italic>in silico</italic> methods to rationalize the drug development pipeline and reduce the risk of late-stage failures. Ultimately, <italic>in silico</italic> drug design accelerates the introduction of effective antimicrobial agents to the market, making it a proven, innovative, and compelling approach to modern drug discovery (<xref ref-type="bibr" rid="B40">Zhang et al., 2022</xref>; <xref ref-type="bibr" rid="B5">Canales et al., 2024</xref>).</p>
<p>In this context, the convergence of benzoxazine and indole structural motifs represents a compelling starting point for developing novel and straightforward synthetic protocols. Such an endeavor has the potential to substantially contribute to the field of synthetic chemistry (<xref ref-type="bibr" rid="B20">Mason et al., 2008</xref>). Developing an efficient method to form C&#x2013;C bonds <italic>via</italic> the arylation of C (sp<sup>2</sup>)&#x2013;H bonds is one of the important and perpetual subjects in organic synthetic chemistry. One significant category of C&#x2013;C bond formation processes involves the established transition metal-catalyzed C-arylation through the activation of the C-X bond (where X &#x3d; I, Br, Cl, and F) in haloarenes. However, this method is plagued by drawbacks such as harsh reaction conditions (high temperature and additives), and the use of costly reagents, diminishing its practicality. Consequently, a sustainable approach was required to address such challenges (<xref ref-type="bibr" rid="B11">Docherty et al., 2023</xref>). In recent years, many efforts have been made to synthesize these frameworks, including photo-redox catalysts (<xref ref-type="bibr" rid="B1">Akula et al., 2018</xref>; <xref ref-type="bibr" rid="B31">Rostoll-Berenguer et al., 2018</xref>), ultrasound techniques (<xref ref-type="bibr" rid="B32">Sharma et al., 2018</xref>), and transition metal catalysts (<xref ref-type="bibr" rid="B26">Pandit et al., 2017</xref>). Radical oxidation in the presence of hypervalent iodine has recently been reported to synthesize these frameworks (<xref ref-type="bibr" rid="B18">Long et al., 2021</xref>). Nevertheless, despite these advances, an efficient, green, and convenient protocol for synthesizing these systems remains a topic of high interest in chemical research (<xref ref-type="bibr" rid="B12">Gra&#x308;&#xdf;le et al., 2016</xref>).</p>
<p>Nucleophilic aromatic substitution (S<sub>N</sub>Ar) is frequently used in synthetic processes involving halogenated aromatics because halogens are an excellent leaving group. However, the reactions often require harsh conditions and expensive reactants such as transition metal catalysts, which makes scientists hesitant to use them in drug synthesis programs due to the cost and environmental impacts involved (<xref ref-type="bibr" rid="B7">Chu et al., 2011</xref>). Microwave-assisted organic synthesis (MAOS) has become one of the most powerful and environmentally friendly tools in synthetic chemistry because of its good features, including reducing the reaction time, energy, and side products and increasing the reaction yields (<xref ref-type="bibr" rid="B29">Rathi et al., 2015</xref>). It can easily catalyze reactions such as cross-couplings that need more power (<xref ref-type="bibr" rid="B39">Zhang et al., 2020</xref>). MAOS is a valuable tool for synthesizing molecules that require challenging, time-consuming, and low-yield methods. Although several methodologies for synthesizing indole alkaloids have been developed, there are no reports for direct, catalyst-free, and microwave-assisted coupling of 3-chloro-1,4-benzoxazin-2-ones with indoles. Previous pathways have utilized one or two of the items mentioned above. Prompted by the aforementioned topics, we present a simple catalyst-free method to prepare the benzoxazine-containing skeleton through microwave irradiation. We also evaluate the potential of these derivatives as antimicrobial agents against <italic>Mycobacterium tuberculosis</italic> and <italic>Streptococcus dysgalactiae</italic>.</p>
</sec>
<sec sec-type="results|discussion" id="s2">
<title>2 Results and discussion</title>
<sec id="s2-1">
<title>2.1 Chemistry</title>
<p>The desired precursors 1,4-benzoxazinediones (<bold>3a-b)</bold> were synthesized using a cyclization method that has been previously reported, between 2-aminophenol and oxalyl chloride (<xref ref-type="scheme" rid="sch1">Scheme 1</xref>) <xref ref-type="bibr" rid="B10">Dickor&#xe9; et al. (1970).</xref> To synthesize the targeted product (<bold>6a)</bold> from the addition&#x2013;elimination reaction, the reaction conditions were optimized and are tabulated in <xref ref-type="table" rid="T1">Table 1</xref>. In this regard, 3-chlorobenzoxazine-2-one <bold>(4a)</bold> and indole were exposed to various solvents in the reflux (<xref ref-type="table" rid="T1">Table 1</xref>, entries 1&#x2013;5), and the highest reaction yield was found in THF. Hence, the effect of the other conditions, including microwave irradiation, ball-milling, and temperature was examined in THF. Over the years, working on the use of AlCl<sub>3</sub> as an efficient and inexpensive reagent for the C&#x2013;C bond forming reactions between heteroaryl chlorides containing&#x2013;C(Cl) &#x3d; N&#x2013;moiety and various arenes or heteroarenes (<xref ref-type="bibr" rid="B16">Kumar et al., 2012</xref>), we also investigated the modal reaction in the presence of AlCl<sub>3</sub> in dichloromethane (<xref ref-type="table" rid="T1">Table 1</xref>, entry 6); however, the expected product was obtained in low yields. Entry 9 shows the optimum conditions for the model reaction.</p>
<fig id="sch1" position="float">
<label>Scheme 1</label>
<caption>
<p>Preparation of 1,4-benzoxazinediones (<bold>3a-b)</bold>
<sup>27</sup>.</p>
</caption>
<graphic xlink:href="FCHEM_fchem-2024-1472342_wc_sch1.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Optimization of the reaction condition for the synthesis of <bold>6a</bold> as the model reaction<xref ref-type="table-fn" rid="Tfn1">
<sup>a</sup>
</xref>.</p>
</caption>
<table>
<thead>
<tr>
<th colspan="5" align="center">
<inline-graphic xlink:href="FCHEM_fchem-2024-1472342_wc_tfx1.tif"/> </th>
</tr>
<tr>
<th align="center">Entry</th>
<th align="center">Solvent</th>
<th align="center">Condition</th>
<th align="center">Time (min)</th>
<th align="center">Yield (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">1</td>
<td align="center">CHCl<sub>3</sub>
</td>
<td align="center">Reflux</td>
<td align="center">120</td>
<td align="center">50</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">THF</td>
<td align="center">Reflux</td>
<td align="center">120</td>
<td align="center">60</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">CH<sub>3</sub>CN</td>
<td align="center">Reflux</td>
<td align="center">180</td>
<td align="center">30</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">DMF</td>
<td align="center">Reflux</td>
<td align="center">180</td>
<td align="center">10</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">MeOH</td>
<td align="center">Reflux</td>
<td align="center">30</td>
<td align="center">10</td>
</tr>
<tr>
<td align="center">
<xref ref-type="table-fn" rid="Tfn2">
<sup>b</sup>
</xref>6</td>
<td align="center">Cl-CH<sub>2</sub>CH<sub>2</sub>-Cl</td>
<td align="center">Reflux</td>
<td align="center">180</td>
<td align="center">40</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">THF</td>
<td align="center">r.t</td>
<td align="center">180</td>
<td align="center">60</td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">THF</td>
<td align="center">Ball-mill</td>
<td align="center">12</td>
<td align="center">70</td>
</tr>
<tr>
<td align="center">
<xref ref-type="table-fn" rid="Tfn3">
<sup>c</sup>
</xref>
<bold>9</bold>
</td>
<td align="center">
<bold>THF</bold>
</td>
<td align="center">
<bold>MW</bold>
</td>
<td align="center">
<bold>7</bold>
</td>
<td align="center">
<bold>85</bold>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="Tfn1">
<label>
<sup>a</sup>
</label>
<p>All reactions were performed using <bold>4a</bold> (0.55&#xa0;mmol), <bold>5a</bold> (1.1&#xa0;mmol), and 2&#xa0;mL of the solvent.</p>
</fn>
<fn id="Tfn2">
<label>
<sup>b</sup>
</label>
<p>AlCl<sub>3</sub>.</p>
</fn>
<fn id="Tfn3">
<label>
<sup>c</sup>
</label>
<p>Optimized reaction conditions.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As shown in <xref ref-type="scheme" rid="sch2">Scheme 2</xref>, by treating 1,4-benzoxazinedione (<bold>3a-b)</bold> with Vilsmeier&#x2013;Haack reagent, a series of 3-chloro-1,4-benzoxazin-2-one derivatives (<bold>4a-b)</bold> were synthesized containing an electrophile center which can undergo the S<sub>N</sub>Ar reaction in the presence of indoles 5a-c as the nucleophile to give the desired 3-aryl-2H-benzo[b][1,4]oxazin-2-ones (<bold>6a-f)</bold>.</p>
<fig id="sch2" position="float">
<label>Scheme 2</label>
<caption>
<p>Two-step preparation of 3-aryl-2H-benzo[b][1,4]oxazin-2-one scaffolds 6a-f via S<sub>N</sub>Ar reactions.</p>
</caption>
<graphic xlink:href="FCHEM_fchem-2024-1472342_wc_sch2.tif"/>
</fig>
<p>For the synthesis of 3-aryl-2<italic>H</italic>-benzo[b][1,4]oxazin-2-ones derivatives, 1,4-benzoxazinediones (<bold>3a-b</bold>) were primarily synthesized by cyclization reactions of 2-aminophenol <bold>(1a-b)</bold> with oxalyl chloride. Subsequently, these 1,4-benzoxazinediones were treated with Vilsmeier&#x2013;Haack reagent to obtain 3-chloro-1,4-benzoxazin-2-one derivatives (<bold>4a-b)</bold>. The desired natural products cephalandole A and derivatives <bold>6a-f</bold> were obtained under the optimal conditions mentioned in <xref ref-type="fig" rid="F2">Figure 2</xref>. A comparison of the results shows that bearing an -CH<sub>3</sub> group on the benzene ring in <bold>4b</bold> produced lower yields of products than those analogs without the -CH<sub>3</sub> substituent, so the presence of electron-donating groups on benzoxazine led to a decrease in product yields. N-methylindole gave the product with a higher yield than indole and 2-methyl indole.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Preparation of compounds <bold>6a-f</bold> <sup>a</sup> (<sup>a</sup>All reactions were performed using imide-chloride <bold>4a-b</bold> (0/55&#xa0;mmol) and indole <bold>5a-c</bold> (1/1&#xa0;mmol) in THF (2&#xa0;mL) under microwave 300&#xa0;W. <sup>b</sup>Benzotriazole (0/55&#xa0;mmol) was used instead of indole <bold>5a-c</bold>).</p>
</caption>
<graphic xlink:href="fchem-12-1472342-g002.tif"/>
</fig>
<p>It would be especially mentioned that benzotriazole is also a suitable substrate for this transformation, and corresponding desired products (7a, 7b) were isolated in 70% and 65% yield, respectively. Some products were characterized by FT-IR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR spectroscopy. Cephalandole A and its derivatives were formed through aromatic substitution of the nucleophile in (<bold>4a-b</bold>) due to the high electrophilicity at the C2 position of the dione. Previous studies have shown that if the nucleophilic moiety is strong enough, it will attack the carbonyl group. It can be concluded that the nucleophile plays an important role in the reaction mechanism.</p>
</sec>
<sec id="s2-2">
<title>2.2 <italic>In silico</italic> studies</title>
<p>Given the notable biological importance of benzoxazine and indole compounds, which have been previously documented as effective antimicrobial agents against <italic>Staphylococcus aureus</italic>, including methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA), as well as <italic>Mycobacterium tuberculosis</italic>, we aimed to investigate their interactions with the protein structures of RelMtb from <italic>M. tuberculosis</italic> (PDB 5XNX) and RelSeq from <italic>Streptococcus dysgalactiae</italic> subsp. equisimilis (PDB 1VJ7). RelMtb is an integral component of the stringent response pathway, a highly conserved bacterial stress response mechanism enabling bacteria to acclimate to conditions of nutrient scarcity and other environmental stressors. Its pivotal role encompasses the synthesis and degradation of the signaling molecule (p)ppGpp. Consequently, pursuing antibacterial agents directed at RelMtb emerges as a promising and strategically sound initiative for targeting <italic>Mycobacterium tuberculosis</italic> (<xref ref-type="bibr" rid="B36">Vercruysse et al., 2011</xref>; <xref ref-type="bibr" rid="B14">Irving and Corrigan, 2018</xref>). Consequently, we employed a library of compounds to investigate their potential binding interactions with RelMtb or its active sites, using molecular docking methods. The molecular docking analysis revealed that compounds <bold>6a-7b</bold> exhibited favorable binding affinities within the active site of RelMtb, with docking scores ranging from &#x2212;8.866&#xa0;kcal/mol to &#x2212;7.067&#xa0;kcal/mol (<xref ref-type="table" rid="T2">Table 2</xref>). Our <italic>in silico</italic> study unequivocally demonstrated the effective involvement of both the heterocyclic ring benzoxazin-2-one and indole in interactions with the RelMtb crystal structure, which was in an unbound state concerning the substrate. Furthermore, in most instances, interactions with His177 were observed.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Results of molecular docking study of <bold>6a-7b</bold> against the <italic>Mycobacterium tuberculosis</italic> binding site.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Entry</th>
<th align="center">Binding energy</th>
<th align="center">Moiety of compound</th>
<th align="center">Residue</th>
<th align="center">Type of interaction</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">
<bold>6a</bold>
</td>
<td align="center">&#x2212;7.067</td>
<td align="center">Indole<break/>Indole</td>
<td align="center">His177<break/>His177</td>
<td align="center">Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6b</bold>
</td>
<td align="center">&#x2212;8.866</td>
<td align="center">C&#x3d;O of benzooxazin-2-one<break/>NH of indole<break/>Indole<break/>Indole</td>
<td align="center">Trp345<break/>Arg346<break/>His177<break/>Tyr306</td>
<td align="center">H-bound<break/>H-bound<break/>Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6c</bold>
</td>
<td align="center">&#x2212;7.811</td>
<td align="center">C&#x3d;O of benzooxazin-2-one</td>
<td align="center">His344</td>
<td align="center">H-bound</td>
</tr>
<tr>
<td align="center">
<bold>6d</bold>
</td>
<td align="center">&#x2212;7.958</td>
<td align="center">C&#x3d;O of benzooxazin-2-one<break/>Indole</td>
<td align="center">His344<break/>Typ306</td>
<td align="center">H-bound<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6e</bold>
</td>
<td align="center">&#x2212;8.267</td>
<td align="center">C&#x3d;O of benzooxazin-2-one<break/>NH of indole<break/>Indole<break/>Indole</td>
<td align="center">Gly307<break/>His177<break/>His177<break/>Tyr306</td>
<td align="center">H-bound<break/>H-bound<break/>Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6f</bold>
</td>
<td align="center">&#x2212;7.134</td>
<td align="center">Benzooxazin-2-one<break/>Indole<break/>Indole<break/>Indole<break/>Indole</td>
<td align="center">His344<break/>Ala350<break/>Lys127<break/>Trp345<break/>Trp345</td>
<td align="center">Pi&#x2013;pi stacking<break/>H-bound<break/>Pi-cation<break/>Pi stacking<break/>Pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>7a</bold>
</td>
<td align="center">&#x2212;6.342</td>
<td align="center">Indole</td>
<td align="center">His177</td>
<td align="center">Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>7b</bold>
</td>
<td align="center">&#x2212;8.150</td>
<td align="center">Benzooxazin-2-one<break/>C&#x3d;O of benzooxazin-2-one</td>
<td align="center">Tyr306<break/>His344</td>
<td align="center">Pi&#x2013;pi stacking<break/>H-bound</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Next, we assessed the impact of the compounds on the RelSeq structure within the synthetic domain (SYN), which was complexed with a GDP (guanosine diphosphate) substrate, to investigate their binding affinity to (p)ppGpp synthetase in a catalytically active state. This analysis observed weaker binding interactions within the RelSeq active site, with docking scores ranging from &#x2212;6.639 to &#x2212;4.061&#xa0;kcal/mol. Notably, both indole and benzoxazin-2-one demonstrated favorable interactions with the binding site. In most instances, interactions with the Tyr308 residue, which was crucial for RelMtb (p)ppGpp synthesis, were also observed (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Results of molecular docking study of <bold>6a-7b</bold> against the <italic>Streptococcus dysgalactiae</italic> binding site.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Entry</th>
<th align="center">Binding energy</th>
<th align="center">Moiety of compound</th>
<th align="center">Residue</th>
<th align="center">Type of interaction</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">
<bold>6e</bold>
</td>
<td align="center">&#x2212;4.161</td>
<td align="center">C&#x3d;O of benzooxazin-2-one Benzooxazin-2-one<break/>Benzooxazin-2-one<break/>Benzooxazin-2-one<break/>Indole<break/>Indole</td>
<td align="center">Arg241<break/>Arg241<break/>Arg269<break/>Trp185<break/>Arg241<break/>Lys243</td>
<td align="center">H-bound<break/>Pi-cation<break/>Pi-cation<break/>Pi&#x2013;pi stacking<break/>Pi-cation<break/>Pi-cation</td>
</tr>
<tr>
<td align="center">
<bold>6a</bold>
</td>
<td align="center">&#x2212;4.692</td>
<td align="center">O of benzooxazin-2-one<break/>C&#x3d;O of benzooxazin-2-one Benzooxazin-2-one<break/>Indole</td>
<td align="center">Trp185<break/>Arg241<break/>Arg327<break/>Lys243</td>
<td align="center">H-bound<break/>H-bound<break/>Pi-cation<break/>Pi-cation</td>
</tr>
<tr>
<td align="center">
<bold>6b</bold>
</td>
<td align="center">&#x2212;6.639</td>
<td align="center">C&#x3d;O of benzooxazin-2-one<break/>C&#x3d;O of benzooxazin-2-one<break/>NH of benzooxazin-2-one Benzooxazin-2-one<break/>NH of indole<break/>Indole<break/>Indole<break/>Indole</td>
<td align="center">Lys184<break/>Trp185<break/>Gln325<break/>Lys304<break/>Ala335<break/>Arg327<break/>Tyr308<break/>Tyr308</td>
<td align="center">H-bound<break/>H-bound<break/>H-bound<break/>Pi-cation<break/>H-bound<break/>Pi-cation<break/>Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6c</bold>
</td>
<td align="center">&#x2212;5.099</td>
<td align="center">Benzo [d][1,2,3]triazole<break/>Indole</td>
<td align="center">Arg269<break/>Arg241</td>
<td align="center">H-bound<break/>Pi-cation</td>
</tr>
<tr>
<td align="center">
<bold>6d</bold>
</td>
<td align="center">&#x2212;4.280</td>
<td align="center">Benzooxazin-2-one<break/>Indole<break/>Indole</td>
<td align="center">Trp185<break/>Trp185<break/>His176</td>
<td align="center">Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking<break/>Pi&#x2013;pi stacking</td>
</tr>
<tr>
<td align="center">
<bold>6e</bold>
</td>
<td align="center">&#x2212;4.615</td>
<td align="center">Benzooxazin-2-one<break/>Benzooxazin-2-one<break/>Benzooxazin-2-one<break/>Indole</td>
<td align="center">Arg269<break/>Arg327<break/>Tyr308<break/>Glu323</td>
<td align="center">Salt bridge<break/>Pi-cation<break/>Pi&#x2013;pi stacking<break/>H-bound</td>
</tr>
<tr>
<td align="center">
<bold>6f</bold>
</td>
<td align="center">&#x2212;4.889</td>
<td align="center">NH of benzoxazine<break/>Benzoxazine<break/>Indole</td>
<td align="center">Arg269<break/>Arg327<break/>Tyr308<break/>Glu323</td>
<td align="center">Salt bridge<break/>Pi-cation<break/>Pi&#x2013;pi stacking<break/>H-bound</td>
</tr>
<tr>
<td align="center">
<bold>7a</bold>
</td>
<td align="center">&#x2212;4.482</td>
<td align="center">Benzo [d][1,2,3]triazole<break/>Benzo [d][1,2,3]triazole</td>
<td align="center">Arg241<break/>Arg269</td>
<td align="center">H-bound<break/>H-bound</td>
</tr>
<tr>
<td align="center">
<bold>7b</bold>
</td>
<td align="center">&#x2212;4.061</td>
<td align="center">Benzo [d][1,2,3]triazole<break/>Benzo [d][1,2,3]triazole<break/>Benzooxazin-2-one</td>
<td align="center">Arg269<break/>Typ308<break/>Lys243</td>
<td align="center">H-bound<break/>Pi&#x2013;pi stacking<break/>H-bound</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The binding pose and interaction of compound <bold>6b</bold> were characterized as potent antibacterial agents against both RelMtb in <italic>Streptococcus dysgalactiae</italic> and the RelSeq structure of <italic>Streptococcus dysgalactiae</italic> illustrated in <xref ref-type="fig" rid="F3">Figure 3</xref>, and according to the obtained results, this compound holds promise for further optimization and development.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Three-dimensional and two-dimensional interaction patterns of compound <bold>6b</bold> within the binding sites of RelMtb <bold>(A, B)</bold> and RelSeq <bold>(C, D)</bold>. <bold>(A)</bold> Three-dimensional interaction of <bold>6b</bold> in RelMtb of the 5XNX binding site. <bold>(B</bold>) Two-dimensional interaction of <bold>6b</bold> in RelMtb of the 5XNX binding site. <bold>(C</bold>) Three-dimensional interaction of <bold>6b</bold> in the RelSeq structure of the 1vj7 binding site. <bold>(D)</bold> Two-dimensional interaction of <bold>6b</bold> in the RelSeq structure of the 1vj7 binding site.</p>
</caption>
<graphic xlink:href="fchem-12-1472342-g003.tif"/>
</fig>
</sec>
<sec id="s2-3">
<title>2.3 Reaction mechanism</title>
<p>The suggested reaction pathway is given below in <xref ref-type="fig" rid="F4">Figure 4</xref>. According to the proposed route, the starting point of the reaction includes the nucleophilic addition of carbon number 3 position of indole to the electrophilic center of 1,4-benzoxazine, and the desired product is obtained after elimination of an HCl molecule.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Suggested pathway of the reaction.</p>
</caption>
<graphic xlink:href="fchem-12-1472342-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s3">
<title>3 Conclusion</title>
<p>In summary, a new environmentally efficient method has been developed to directly couple 3-chloro-1,4-benzoxazin-2-one with indoles, enabling the synthesis of diverse functionalized benzoxazines This process, conducted under microwave irradiation, is characterized by its simplicity, safety, and metal-free nature, yielding high-purity products in significant quantities. Additionally, this method facilitates access to the natural product cephalandole A. Furthermore, <italic>in silico</italic> approaches demonstrated that 3-aryl-2<italic>H</italic>-benzo[b][1,4]oxazin-2-ones have potential antimicrobial activity against <italic>Mycobacterium tuberculosis</italic> and <italic>Streptococcus dysgalactiae</italic>. This sustainable, eco-friendly, and expeditious methodology can be considered an alternative means for development of novel biologically active agents.</p>
</sec>
<sec sec-type="materials|methods" id="s4">
<title>4 Method and materials</title>
<sec id="s4-1">
<title>4.1 General procedure of the synthesis of 1,4-benzoxaxinedione 3a</title>
<p>To a solution of oxalyl chloride (4.2&#xa0;mmol) in o-dichlorobenzene (3&#xa0;mL), 2-aminophenol (3&#xa0;mmol) was added at room temperature, and the reaction mixture was stirred at 120&#xb0;C for 3&#xa0;h. As the reaction progressed, HCl vapors formed, and a slurry suspension was produced. The progress of the reaction was monitored by thin-layer chromatography (TLC). Once the reaction was complete, the white precipitate was filtered and first washed with o-dichlorobenzene and then with toluene. The product was obtained as a white powder (90%).</p>
<sec id="s4-1-1">
<title>4.1.1 General procedure of the synthesis of 3-chloro-1,4-benzoxazine-2-one (4a-b)</title>
<p>To a solution of (2.45&#xa0;mmol) <bold>3a-b</bold> in dry toluene (5&#xa0;mL) after adding (0.1&#xa0;mL) DMF, 0.2&#xa0;mL (2.75&#xa0;mmol) thionyl chloride was added dropwise at the boiling point of the solvent. The solution was stirred at 120&#xb0;C for 1&#xa0;h. The reaction mixture was evaporated under a vacuum. The residue was purified by recrystallization using benzene/petroleum ether (1:2) to afford the desired product <bold>4</bold> as a colorless crystal (70%&#x2013;80%).</p>
</sec>
<sec id="s4-1-2">
<title>4.1.2 The general procedure of the synthesis of cephalandole A and analogous (6a-f)</title>
<p>To (0.55&#xa0;mmol) 3-chloro-1,4-benzoxazine-2-one (<bold>4a-b)</bold> and (1.1&#xa0;mmol) indole (<bold>5a-c)</bold> was added (2&#xa0;mL) THF. The mixture was placed in a microwave synthesizer with a power of 300 w and a temperature of 60&#xb0;C for 6&#x2013;12&#xa0;min. The progress of the reaction was monitored by thin-layer chromatography (EtOAc/n-hexane 3:20). After the completion of the reaction, the solvent was removed, and the crude product was recrystallized twice from ethanol to afford the pure cephalandole A and its analogous <bold>6a-f</bold> in good yields (55%&#x2013;82%).</p>
</sec>
<sec id="s4-1-3">
<title>4.1.3 The general procedure of the synthesis of 7a-b</title>
<p>To (0.55&#xa0;mmol) <bold>4a-b</bold> and (1.1&#xa0;mmol) benzotriazole was added (2&#xa0;mL) THF. The mixture was placed in a microwave with a power of 300 w and a temperature of 60&#xb0;C for 11&#x2013;12&#xa0;min. Then, the solvent was removed, and the desired product <bold>7a-b</bold> was precipitated. The crude product was washed with ethanol and dried <italic>in vacuo</italic> (65%&#x2013;70%).</p>
</sec>
<sec id="s4-1-4">
<title>4.1.2 2<italic>H</italic>-benzo[b][1,4]oxazine-2,3(4H)-dione (3a)</title>
<p>Yield 90%; white powder; mp: 275&#xb0;C&#x2013;276&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 1700, 1775; <sup>1</sup>H-NMR (499&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 11.89 (s, 1H), 7.25 (d, J &#x3d; 8.0&#xa0;Hz, 1H), 7.20 (t, J &#x3d; 7.6&#xa0;Hz, 1H), 7.11 (t, J &#x3d; 8.2&#xa0;Hz, 2H); <sup>13</sup>C NMR (126&#xa0;MHz, DMSO-d<sub>6</sub>) &#x3b4; 153.99, 150.83, 140.56, 125.57, 124.84, 123.11, 116.28, and 115.67.</p>
</sec>
<sec id="s4-1-5">
<title>4.1.3 6-methyl-2<italic>H</italic>-benzo[b][1,4]oxazine-2,3(4H)-dione (3b)</title>
<p>Yield 90%; white powder; mp: 236&#xb0;C&#x2013;239&#xb0;C, <sup>1</sup>H-NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>6</sub>) &#x3b4; 11.87 (s, 1H), 7.12 (d, <italic>J</italic> &#x3d; 8.2&#xa0;Hz, 1H), 6.97&#x2013;6.77 (m, 2H), 2.28 (s, 3H); <sup>13</sup>C NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 154.47, 151.30, 138.97, 134.67, 125.59, 124.11, 116.45, 116.07, and 20.89.</p>
</sec>
<sec id="s4-1-6">
<title>4.1.4 3-chloro-1,4-benzoxazin-2-one (4a)</title>
<p>Yield 70%; colorless crystal; mp: 138&#xb0;C&#x2013;140&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 1760, <sup>1</sup>H-NMR (499&#xa0;MHz, acetone-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 7.74 (dd, J &#x3d; 8.0, 1.7&#xa0;Hz, 1H), 7.68 (td, J &#x3d; 7.9, 1.7&#xa0;Hz, 1H), 7.50 (td, J &#x3d; 7.7, 1.3&#xa0;Hz, 1H), 7.44 (dd, J &#x3d; 8.2, 1.4&#xa0;Hz, 1H); <sup>13</sup>C-NMR (126&#xa0;MHz, acetone-d<sub>6</sub>) &#x3b4; 149/35, 146/83, 145/80, 131/71, 130/64, 128/35, 125/77, and 116/35.</p>
</sec>
<sec id="s4-1-7">
<title>4.1.5 3-chlor-6-methyl-2-oxo-1,4-benzoxazin (4b)</title>
<p>Yield 80%; colorless crystal; mp: 138&#xb0;C&#x2013;139&#xb0;C, <sup>1</sup>H-NMR (400&#xa0;MHz, acetone-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 7.15 (d, J &#x3d; 8.3&#xa0;Hz, 1H), 7.05 (d, J &#x3d; 2.0&#xa0;Hz, 1H), 7.00 (dd, J &#x3d; 8.3, 2.0&#xa0;Hz, 1H), 2.35 (s, 3H); <sup>13</sup>C-NMR (101&#xa0;MHz, acetone) &#x3b4; 153.53, 150.28, 138.83, 135.02, 124.98, 124.16, 116.23, 115.76, and 19.95.</p>
</sec>
<sec id="s4-1-8">
<title>4.1.6 3-(1<italic>H</italic>-indol-3-yl)-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (cephalandole A) (6a): yield 80%; bright yellow.</title>
<p>Amorphous powder; mp: 237&#xb0;C&#x2013;238&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 3,301, 1718, 1606,1533,1,431&#xa0;cm<sup>-1</sup>, <sup>1</sup>H-NMR (499&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 11.98 (s, 1H), 8.79&#x2013;8.73 (m, 1H), 8.70 (d, J &#x3d; 3.0&#xa0;Hz, 1H), 7.89&#x2013;7.84 (m, 1H), 7.61&#x2013;7.50 (m, 1H), 7.50&#x2013;7.45 (m, 1H), 7.45&#x2013;7.39 (m, 2H), 7.31&#x2013;7.23 (m, 2H); <sup>13</sup>C-NMR (126&#xa0;MHz, DMSO-d<sub>6</sub>) &#x3b4; 152.51, 148.37, 145.33, 137.05, 134.21, 132.41, 129.13, 128.17, 126.44, 125.79, 123.51, 123.29, 121.97, 116.37, 112.66, and 111.04, anal. Calcd. For C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub> (C, 73.27; H, 3.84; N, 10.68); found: (C, 73.54; H, 3.78; N, 10.57).</p>
</sec>
<sec id="s4-1-9">
<title>4.1.7 3-(1<italic>H</italic>-indol-3-yl)-6-methyl-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (6b)</title>
<p>Yield 70%; brown to yellow powder; mp: 257&#xb0;C&#x2013;259&#xb0;C, <sup>1</sup>H-NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 11.98 (s, 1H), 8.77 (dd, J &#x3d; 7.3, 2.1&#xa0;Hz, 1H), 8.69 (d, J &#x3d; 3.0&#xa0;Hz, 1H), 7.67 (d, J &#x3d; 1.7&#xa0;Hz, 1H), 7.54 (dd, J &#x3d; 7.3, 1.8&#xa0;Hz, 1H), 7.40&#x2013;7.09 (m, 4H), 2.42 (s, 3H); <sup>13</sup>C-NMR (101&#xa0;MHz, DMSO) &#x3b4; 152.64, 148.22, 143.24, 137.03, 135.16, 134.08, 132.07, 129.91, 128.05, 126.45, 123.48, 123.32, 121.91, 115.95, 112.65, 111.09, and 20.81, anal. Calcd. For C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> (C, 73.90; H, 4.38; N, 10.14); found: (C, 73.78; H, 4.26; N, 10.09).</p>
</sec>
<sec id="s4-1-10">
<title>4.1.8 3-(1-methyl-1<italic>H</italic>-indol-3-yl)-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (6c)</title>
<p>Yield 82%; bright yellow crystal; mp: 203&#xb0;C&#x2013;206&#xb0;C, <sup>1</sup>H-NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>6</sub>) &#x3b4; 8.81&#x2013;8.75 (m, 1H), 8.72 (s, 1H), 7.85 (dd, <italic>J</italic> &#x3d; 7.6, 1.7&#xa0;Hz, 1H), 7.59 (dd, <italic>J</italic> &#x3d; 7.3, 1.7&#xa0;Hz, 1H), 7.52&#x2013;7.27 (m, 5H), 3.94 (s, 3H); <sup>13</sup>C-NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 152.47, 148.02, 145.30, 137.87, 137.64, 132.41, 129.10, 128.14, 126.90, 125.79, 123.58, 123.44, 122.31, 116.35, 111.04, 109.98, and 33.63, anal. Calcd. For C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> (C, 73.90; H, 4.38; N, and 10.14); found: (C, 74.11; H, 4.42; N, 10.09).</p>
</sec>
<sec id="s4-1-11">
<title>4.1.9 6-methyl-3-(1-methyl-1<italic>H</italic>-indol-3-yl)-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (6d)</title>
<p>Yield 75%; yellow solid; mp: 225&#xb0;C&#x2013;227&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 2,908, 1725, 1527,744, <sup>1</sup>H-NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>6</sub>) &#x3b4; 8.82&#x2013;8.75 (m, 1H), 8.71 (s, 1H), 7.68 (s, 1H), 7.63&#x2013;7.56 (m, 1H), 7.39&#x2013;7.25 (m, 4H), 3.94 (s, 3H), 2.43 (s, 3H), <sup>13</sup>C-NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 152.63, 147.92, 143.25, 137.76, 137.64, 135.19, 132.10, 129.92, 128.04, 126.92, 123.57, 123.45, 122.27, 115.97, 111.05, 110.03, 33.63, and 20.81, anal. Calcd. For C<sub>18</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> (C, 74.47; H, 4.86; N, 9.65); found: (C, 74.18; H, 4.85; N, 9.68).</p>
</sec>
<sec id="s4-1-12">
<title>4.1.10 3-(2-methyl-1<italic>H</italic>-indol-3-yl)-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (6e)</title>
<p>Yield 60%; red to brown crystal; mp: 184&#xb0;C&#x2013;185&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 3,323, 1730, 1453,733, <sup>1</sup>H NMR (499&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 11.69 (s, 1H), 7.87 (d, J &#x3d; 7.9&#xa0;Hz, 1H), 7.77 (dt, J &#x3d; 7.9, 1.5&#xa0;Hz, 1H), 7.55&#x2013;7.47 (m, 1H), 7.47&#x2013;7.38 (m, 2H), 7.36 (d, J &#x3d; 7.9&#xa0;Hz, 1H), 7.15&#x2013;7.03 (m, 2H), 2.59 (s,3H), anal. Calcd. For C<sub>17</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub> (C, 73.90; H, 4.38; N, 10.14); found: (C, 73.75; H, 4.37; N, 10.11).</p>
</sec>
<sec id="s4-1-13">
<title>4.1.11 6-methyl-3-(2-methyl-1<italic>H</italic>-indol-3-yl)-2<italic>H</italic>-benzo[b][1,4]oxazine (6f)</title>
<p>Yield 55%; red to brown crystal; mp: 203&#xb0;C&#x2013;204&#xb0;C, <sup>1</sup>H NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 11.71 (s, 1H), 7.92&#x2013;7.85 (m, 1H), 7.61&#x2013;7.56 (m, 1H), 7.38 (d, J &#x3d; 7.9&#xa0;Hz, 1H), 7.30 (d, J &#x3d; 1.3&#xa0;Hz, 2H), 7.17&#x2013;7.03 (m, 2H), 2.60 (s, 3H), 2.41 (s, 3H), <sup>13</sup>C NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 152.88, 150.52, 144.02, 141.37, 135.59, 135.03, 131.99, 130.49, 128.23, 128.00, 121.80, 121.45, 120.46, 115.95, 111.25, 108.79, 20.76, and 14.86, anal. Calcd. For C<sub>18</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> (78.24; H, 5.84; N, 10.14); found: (C, 77.94; H, 5.79; N, 10.10).</p>
</sec>
<sec id="s4-1-14">
<title>4.1.12 3-(1<italic>H</italic>-benzo[d][1,2,3]triazol-1-yl)-2H-benzo[b][1,4]oxazin-2-one (7a)</title>
<p>Yield 70%; yellowish crystal; mp: 191&#xb0;C&#x2013;192&#xb0;C, IR (KBr, cm<sup>&#x2212;1</sup>) v &#x3d; 1751, 1,182, 994, 749, <sup>1</sup>H-NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 8.24 (t, J &#x3d; 8.7&#xa0;Hz, 2H), 7.93 (dd, J &#x3d; 7.9, 1.5&#xa0;Hz, 1H), 7.73 (ddd, J &#x3d; 22.5, 8.7, 7.1, 1.3&#xa0;Hz, 2H), 7.59 (ddt, J &#x3d; 6.9, 3.8, 1.8&#xa0;Hz, 2H), 7.53 (td, J &#x3d; 7.6, 1.4&#xa0;Hz, 1H), <sup>13</sup>C-NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 148.99, 147.04, 145.41, 142.25, 132.64, 132.14, 130.05, 129.72, 129.22, 126.27, 126.07, 120.06, 116.76, and 114.80, anal. Calcd. For C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> (C, 63.64; H, 3.05; N, 21.20); found: (C, 63.46; H, 3.04; N, 21.42).</p>
</sec>
<sec id="s4-1-15">
<title>4.1.13 3-(1<italic>H</italic>-benzo[d][1,2,3]triazol-1-yl)-6-methyl-2<italic>H</italic>-benzo[b][1,4]oxazin-2-one (7b)</title>
<p>Yield 65%; deep yellow crystal; mp: 194&#xb0;C&#x2013;195&#xb0;C, <sup>1</sup>H NMR (400&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 8.28&#x2013;8.18 (m, 2H), 7.79&#x2013;7.70 (m, 2H), 7.59 (ddd, J &#x3d; 8.2, 7.0, 1.1&#xa0;Hz, 1H), 7.54&#x2013;7.43 (m, 2H), 2.44 (s, 3H), <sup>13</sup>C NMR (101&#xa0;MHz, DMSO-<italic>d</italic>
<sub>
<italic>6</italic>
</sub>) &#x3b4; 149.08, 145.39, 144.99, 142.12, 135.84, 132.89, 132.63, 129.72, 129.66, 128.95, 126.04, 120.04, 116.36, 114.78, and 20.70, anal. Calcd. For C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub> (C, 64.74; H, 3.62; N, 20.13); found: (C, 64.9; H, 3.88; N, 20.05).</p>
</sec>
</sec>
<sec id="s4-2">
<title>4.2 Molecular docking study</title>
<p>Molecular docking analyses were conducted using the Schr&#xf6;dinger Maestro software [93]. The analysis utilized the protein structures of RelMtb from <italic>M. tuberculosis</italic> (PDB: <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/5xnx">https://www.rcsb.org/structure/5xnx</ext-link>) and RelSeq from <italic>Streptococcus dysgalactiae</italic> subsp. equisimilis (PDB: <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/1vj7">https://www.rcsb.org/structure/1vj7</ext-link>). These structures were initially optimized and minimized with the Protein Preparation Wizard and the OPLS3 force field. Additionally, all derivatives&#x2019; structures were optimized using LigPrep. The molecular docking was executed in the IFD mode, with the ligand considered flexible and employing the OPLS-2005 force field, while maintaining default settings for other parameters. A grid for IFD calculation was generated based on the binding site. Up to five poses with receptor and ligand van der Waals radii of 0.7 and 0.5, respectively, were considered. Residues within a 15&#xa0;&#xc5; radius of the crystallographic ligands at the active site underwent refinement, followed by side-chain optimization. Structures with a prime energy exceeding 30&#xa0;kcal/mol were eliminated.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The datasets generated and/or analyzed during the current study are available in the Worldwide ProteinData Bank with PDB ID of 5XNX (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/5XNX">https://www.rcsb.org/structure/5XNX</ext-link>) and 1vj7 (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/1vj7">https://www.rcsb.org/structure/1vj7</ext-link>) repository.</p>
</sec>
<sec sec-type="author-contributions" id="s6">
<title>Author contributions</title>
<p>FS: data curation, investigation, methodology, validation, and writing&#x2013;original draft. ME: investigation, visualization, and writing&#x2013;original draft. MN: software, validation, and writing&#x2013;original draft. SJ: conceptualization, supervision, and writing&#x2013;review and editing. AI: data curation, software, visualization, and writing&#x2013;original draft. MM: resources and writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s7">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchem.2024.1472342/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchem.2024.1472342/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet2.zip" id="SM1" mimetype="application/zip" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet1.docx" id="SM2" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akula</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>B.-C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G.-H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Visible-light-induced C (sp 3)&#x2013;H activation for a C&#x2013;C bond forming reaction of 3, 4-dihydroquinoxalin-2 (1 H)-one with nucleophiles using oxygen with a photoredox catalyst or under catalyst-free conditions</article-title>. <source>RSC Adv.</source> <volume>8</volume> (<issue>35</issue>), <fpage>19580</fpage>&#x2013;<lpage>19584</lpage>. <pub-id pub-id-type="doi">10.1039/c8ra03259a</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batt</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Moorey</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Besra</surname>
<given-names>G. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antibiotics and resistance: the two-sided coin of the mycobacterial cell wall</article-title>. <source>Cell Surf.</source> <volume>6</volume>, <fpage>100044</fpage>. <pub-id pub-id-type="doi">10.1016/j.tcsw.2020.100044</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyd</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Frei</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>11</volume>, <fpage>684515</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2021.684515</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burchak</surname>
<given-names>O. N.</given-names>
</name>
<name>
<surname>Pihive</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Maigre</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guinchard</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bouhours</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jolivalt</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Synthesis and evaluation of 1-(1H-indol-3-yl)ethanamine derivatives as new antibacterial agents</article-title>. <source>Bioorg. and Med. Chem.</source> <volume>19</volume> (<issue>10</issue>), <fpage>3204</fpage>&#x2013;<lpage>3215</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2011.03.060</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canales</surname>
<given-names>C. S. C.</given-names>
</name>
<name>
<surname>Pavan</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>dos Santos</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Pavan</surname>
<given-names>F. R.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>
<italic>In silico</italic> drug design strategies for discovering novel tuberculosis therapeutics</article-title>. <source>Expert Opin. Drug Discov.</source> <volume>19</volume> (<issue>4</issue>), <fpage>471</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2024.2319042</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Groundwater</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Hibbs</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A guide to <italic>in silico</italic> drug design</article-title>. <source>Pharmaceutics</source> <volume>15</volume> (<issue>1</issue>), <fpage>49</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics15010049</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Palladium (II)&#x2010;Catalyzed one&#x2010;pot syntheses of 9&#x2010;(Pyridin&#x2010;2&#x2010;yl)&#x2010;9H&#x2010;carbazoles through a tandem C- H activation/C- X (X&#x3d; C or N) formation process</article-title>. <source>Chemistry&#x2013;A Eur. J.</source> <volume>17</volume> (<issue>48</issue>), <fpage>13613</fpage>&#x2013;<lpage>13620</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201101528</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciszewski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zegarski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>E. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Streptococcus dysgalactiae subsp. equisimilis isolated from infections in dogs and humans: are current subspecies identification criteria accurate?</article-title> <source>Curr. Microbiol.</source> <volume>73</volume> (<issue>5</issue>), <fpage>684</fpage>&#x2013;<lpage>688</lpage>. <pub-id pub-id-type="doi">10.1007/s00284-016-1113-x</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Commons</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Smeesters</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Proft</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Robins-Browne</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Streptococcal superantigens: categorization and clinical associations</article-title>. <source>Trends Mol. Med.</source> <volume>20</volume> (<issue>1</issue>), <fpage>48</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2013.10.004</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickor&#xe9;</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasse</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>K. D.</given-names>
</name>
</person-group> (<year>1970</year>). <article-title>&#xdc;berg&#xe4;nge aus der Benzoxazol&#x2010;in die Benzoxazin&#x2010;Reihe und umgekehrt, II1 Benzoxazol&#x2010;2&#x2010;carbons&#xe4;ure&#x2010;Derivate aus 2.3&#x2010;Dioxo&#x2010;1.4&#x2010;benzoxazinen</article-title>. <source>Justus Liebigs Ann. Chem.</source> <volume>733</volume> (<issue>1</issue>), <fpage>70</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1002/jlac.19707330108</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Docherty</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Lister</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Mcarthur</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Findlay</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Domingo-Legarda</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kenyon</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Transition-metal-catalyzed C&#x2013;H bond activation for the formation of C&#x2013;C bonds in complex molecules</article-title>. <source>Chem. Rev.</source> <volume>123</volume> (<issue>12</issue>), <fpage>7692</fpage>&#x2013;<lpage>7760</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.2c00888</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gra&#x308;&#xdf;le</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vanderheiden</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hodapp</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bulat</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nieger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Solid phase synthesis of (benzannelated) six-membered heterocycles via cyclative cleavage of resin-bound pseudo-oxazolones</article-title>. <source>Org. Lett.</source> <volume>18</volume> (<issue>15</issue>), <fpage>3598</fpage>&#x2013;<lpage>3601</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.6b01609</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoemann</surname>
<given-names>M. Z.</given-names>
</name>
<name>
<surname>Kumaravel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>R. F.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sidhu</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Potent <italic>in vitro</italic> methicillin-resistant <italic>Staphylococcus aureus</italic> activity of 2-(1H-indol-3-yl) quinoline derivatives</article-title>. <source>Bioorg Med. Chem. Lett.</source> <volume>10</volume> (<issue>23</issue>), <fpage>2675</fpage>&#x2013;<lpage>2678</lpage>. <pub-id pub-id-type="doi">10.1016/s0960-894x(00)00542-4</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irving</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Corrigan</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Triggering the stringent response: signals responsible for activating (p)ppGpp synthesis in bacteria</article-title>. <source>Microbiol. Read.</source> <volume>164</volume> (<issue>3</issue>), <fpage>268</fpage>&#x2013;<lpage>276</lpage>. <pub-id pub-id-type="doi">10.1099/mic.0.000621</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Jabalia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rani</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). &#x201c;<article-title>
<italic>In silico</italic> approach in drug design and drug discovery: an update</article-title>,&#x201d; in <source>Innovations and implementations of computer aided drug discovery strategies in rational drug design</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Singh</surname>
<given-names>S. K.</given-names>
</name>
</person-group> (<publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer Singapore</publisher-name>), <fpage>245</fpage>&#x2013;<lpage>271</lpage>.</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Sreenivas</surname>
<given-names>B. Y.</given-names>
</name>
<name>
<surname>Gorja</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Kapavarapu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rambabu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>C&#x2013;C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl) quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors</article-title>. <source>Bioorg. and Med. Chem.</source> <volume>20</volume> (<issue>7</issue>), <fpage>2199</fpage>&#x2013;<lpage>2207</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2012.02.027</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushwaha</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Kushwaha</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Karpoormath</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mahlalela</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Shinde</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>One-pot, multicomponent, diastereoselective, green synthesis of 3, 4-dihydro-2 H-benzo [b] [1, 4] oxazine analogues</article-title>. <source>J. Org. Chem.</source> <volume>85</volume> (<issue>12</issue>), <fpage>8221</fpage>&#x2013;<lpage>8229</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.0c00463</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hypervalent iodine (III)-Promoted radical oxidative C&#x2013;H annulation of arylamines with &#x3b1;-keto acids</article-title>. <source>J. Org. Chem.</source> <volume>86</volume> (<issue>17</issue>), <fpage>12084</fpage>&#x2013;<lpage>12092</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.1c01424</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>L&#xf3;pez-Iglesias</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Busto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gotor</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gotor-Fern&#xe1;ndez</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Chemoenzymatic asymmetric synthesis of 1, 4-benzoxazine derivatives: application in the synthesis of a levofloxacin precursor</article-title>. <source>J. Org. Chem.</source> <volume>80</volume> (<issue>8</issue>), <fpage>3815</fpage>&#x2013;<lpage>3824</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.5b00056</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Janosik</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Synthetic studies of cephalandole alkaloids and the revised structure of cephalandole A</article-title>. <source>J. Nat. Prod.</source> <volume>71</volume> (<issue>8</issue>), <fpage>1447</fpage>&#x2013;<lpage>1450</lpage>. <pub-id pub-id-type="doi">10.1021/np800334j</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathavan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamajala</surname>
<given-names>R. B.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Base promoted coupling of &#x3b1;-ketoacids and 2-substituted aromatic amines: green synthesis of diverse benzoxazoles, benzothiazoles, quinoxalinones and benzoxazinones and its practical application</article-title>. <source>Synth. Commun.</source> <volume>54</volume> (<issue>1</issue>), <fpage>50</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1080/00397911.2023.2280599</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miethke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pieroni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Br&#xf6;nstrup</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hammann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Halby</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Towards the sustainable discovery and development of new antibiotics</article-title>. <source>Nat. Rev. Chem.</source> <volume>5</volume> (<issue>10</issue>), <fpage>726</fpage>&#x2013;<lpage>749</lpage>. <pub-id pub-id-type="doi">10.1038/s41570-021-00313-1</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitscher</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P. N.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Pernet</surname>
<given-names>A. G.</given-names>
</name>
</person-group> (<year>1987</year>). <article-title>Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2, 3-dihydro-7H-pyrido [1, 2, 3-de]-1, 4-benzoxazine-6-carboxylic acid (ofloxacin)</article-title>. <source>J. Med. Chem.</source> <volume>30</volume> (<issue>12</issue>), <fpage>2283</fpage>&#x2013;<lpage>2286</lpage>. <pub-id pub-id-type="doi">10.1021/jm00395a017</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nevanlinna</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aittoniemi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luukkaala</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rantala</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Major risk factors for Streptococcus dysgalactiae subsp. equisimilis bacteremia: a population-based study</article-title>. <source>BMC Infect. Dis.</source> <volume>23</volume> (<issue>1</issue>), <fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-023-07992-9</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieto</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Lupton</surname>
<given-names>H. K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Indole and indoline scaffolds in antimicrobials: overview, synthesis and recent advances in antimicrobial research</article-title>. <source>Curr. Med. Chem.</source> <volume>28</volume> (<issue>24</issue>), <fpage>4828</fpage>&#x2013;<lpage>4844</lpage>. <pub-id pub-id-type="doi">10.2174/0929867327666201102114923</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandit</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. R.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Copper-catalyzed direct coupling of benzoxazin-2-ones with indoles for the synthesis of diverse 3-indolylbenzoxazin-2-ones: access to natural cephalandole A</article-title>. <source>RSC Adv.</source> <volume>7</volume> (<issue>87</issue>), <fpage>55288</fpage>&#x2013;<lpage>55295</lpage>. <pub-id pub-id-type="doi">10.1039/c7ra10634c</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patil</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Serhii</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Garzino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gobert</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Giorgio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raimundo</surname>
<given-names>J.-M.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Synthesis and antimicrobial testing of 5-fluorouracil derivatives</article-title>. <source>Arch. Pharm. Weinh.</source> <volume>356</volume> (<issue>7</issue>), <fpage>2300103</fpage>. <pub-id pub-id-type="doi">10.1002/ardp.202300103</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>H.-L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>W.-Y.</given-names>
</name>
<name>
<surname>Ravindar</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rakesh</surname>
<given-names>K. P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Indole-based derivatives as potential antibacterial activity against methicillin-resistance <italic>Staphylococcus aureus</italic> (MRSA)</article-title>. <source>Eur. J. Med. Chem.</source> <volume>194</volume>, <fpage>112245</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112245</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rathi</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Gawande</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Zboril</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Microwave-assisted synthesis&#x2013;catalytic applications in aqueous media</article-title>. <source>Coord. Chem. Rev.</source> <volume>291</volume>, <fpage>68</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2015.01.011</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roney</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohd Aluwi</surname>
<given-names>M. F. F.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>The importance of in-silico studies in drug discovery</article-title>. <source>Intell. Pharm.</source> <volume>2</volume> (<issue>4</issue>), <fpage>578</fpage>&#x2013;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1016/j.ipha.2024.01.010</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rostoll-Berenguer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blay</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Vila</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>9, 10-phenanthrenedione as visible-light photoredox catalyst: a green methodology for the functionalization of 3, 4-dihydro-1, 4-benzoxazin-2-ones through a Friedel-Crafts reaction</article-title>. <source>Catalysts</source> <volume>8</volume> (<issue>12</issue>), <fpage>653</fpage>. <pub-id pub-id-type="doi">10.3390/catal8120653</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Jaiswal</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Saran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mathur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swami</surname>
<given-names>A. K.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>An efficient synthesis and biological evaluation of novel analogues of natural product Cephalandole A: a new class of antimicrobial and antiplatelet agents</article-title>. <source>Fitoterapia</source> <volume>129</volume>, <fpage>13</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2018.06.003</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>New crystalline salt forms of levofloxacin: conformational analysis and attempts towards the crystal structure prediction of the anhydrous form</article-title>. <source>CrystEngComm</source> <volume>16</volume> (<issue>20</issue>), <fpage>4215</fpage>&#x2013;<lpage>4230</lpage>. <pub-id pub-id-type="doi">10.1039/c4ce00263f</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Benzoxazine: a privileged scaffold in medicinal chemistry</article-title>. <source>Curr. Med. Chem.</source> <volume>30</volume> (<issue>4</issue>), <fpage>372</fpage>&#x2013;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.2174/0929867329666220705140846</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uddin</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Khusro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zidan</surname>
<given-names>B. M. R. M.</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Emran</surname>
<given-names>T. B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects</article-title>. <source>J. Infect. Public Health</source> <volume>14</volume> (<issue>12</issue>), <fpage>1750</fpage>&#x2013;<lpage>1766</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2021.10.020</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vercruysse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fauvart</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jans</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beullens</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Braeken</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cloots</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Stress response regulators identified through genome-wide transcriptome analysis of the (p)ppGpp-dependent response in Rhizobium etli</article-title>. <source>Genome Biol.</source> <volume>12</volume> (<issue>2</issue>), <fpage>R17</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2011-12-2-r17</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waisser</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kubicov&#xe1;</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Buchta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kubanova</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bajerova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jiraskova</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>
<italic>In vitro</italic> antifungal activity of 3-phenyl-2 H-benzoxazine-2, 4 (3 H)-diones</article-title>. <source>Folia Microbiol.</source> <volume>47</volume>, <fpage>488</fpage>&#x2013;<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1007/bf02818786</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Indole reverses intrinsic antibiotic resistance by activating a novel dual-function importer</article-title>. <source>mBio</source> <volume>10</volume> (<issue>3</issue>), <fpage>006766</fpage>&#x2013;<lpage>e719</lpage>. <pub-id pub-id-type="doi">10.1128/mbio.00676-19</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>N. T. S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Microwave-assisted aqueous carbon&#x2013;carbon cross-coupling reactions of aryl chlorides catalysed by reduced graphene oxide supported palladium nanoparticles</article-title>. <source>Green Chem.</source> <volume>22</volume> (<issue>10</issue>), <fpage>3239</fpage>&#x2013;<lpage>3247</lpage>. <pub-id pub-id-type="doi">10.1039/d0gc00833h</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>
<italic>In silico</italic> methods for identification of potential therapeutic targets</article-title>. <source>Interdiscip. Sci.</source> <volume>14</volume> (<issue>2</issue>), <fpage>285</fpage>&#x2013;<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1007/s12539-021-00491-y</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>T.-F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.-L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.-Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Construction of benzoxazinones from anilines and their derivatives</article-title>. <source>Org. Lett.</source> <volume>25</volume> (<issue>27</issue>), <fpage>4968</fpage>&#x2013;<lpage>4973</lpage>. <pub-id pub-id-type="doi">10.1021/acs.orglett.3c01511</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zumbra&#x308;gel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Machui</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nonnhoff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gro&#x308;ger</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Enantioselective biocatalytic reduction of 2 H-1, 4-benzoxazines using imine reductases</article-title>. <source>J. Org. Chem.</source> <volume>84</volume> (<issue>3</issue>), <fpage>1440</fpage>&#x2013;<lpage>1447</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.8b02867</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>